BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thanki K, van Eetvelde D, Geyer A, Fraire J, Hendrix R, Van Eygen H, Putteman E, Sami H, de Souza Carvalho-Wodarz C, Franzyk H, Nielsen HM, Braeckmans K, Lehr CM, Ogris M, Foged C. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. J Control Release 2019;310:82-93. [PMID: 31398360 DOI: 10.1016/j.jconrel.2019.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Chow MYT, Qiu Y, Lam JKW. Inhaled RNA Therapy: From Promise to Reality. Trends Pharmacol Sci 2020;41:715-29. [PMID: 32893004 DOI: 10.1016/j.tips.2020.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Xia C, Li M, Ran G, Wang X, Lu Z, Li T, Tang X, Zhang Z, He Q. Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase A silencing for enhanced cancer immunochemotherapy. J Control Release 2021;335:557-74. [PMID: 34051289 DOI: 10.1016/j.jconrel.2021.05.034] [Reference Citation Analysis]
3 Wu L, Rodríguez-Rodríguez C, Cun D, Yang M, Saatchi K, Häfeli UO. Quantitative comparison of three widely-used pulmonary administration methods in vivo with radiolabeled inhalable nanoparticles. Eur J Pharm Biopharm 2020;152:108-15. [PMID: 32437751 DOI: 10.1016/j.ejpb.2020.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Xu Y, Thakur A, Zhang Y, Foged C. Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects. Pharmaceutics 2021;13:177. [PMID: 33525500 DOI: 10.3390/pharmaceutics13020177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vervaeke P, Borgos SE, Sanders NN, Combes F. Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics. Adv Drug Deliv Rev 2022;184:114236. [PMID: 35351470 DOI: 10.1016/j.addr.2022.114236] [Reference Citation Analysis]
6 Bohr A, Tsapis N, Foged C, Andreana I, Yang M, Fattal E. Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model. Eur J Pharm Biopharm 2020;156:114-20. [PMID: 32798665 DOI: 10.1016/j.ejpb.2020.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
7 Xiong Q, Li Y, Zhou K, Chen P, Guo H, Chen L, Ding J, Song T, Shi J. Optimized fluorodendrimer-incorporated hybrid lipid–polymer nanoparticles for efficient siRNA delivery. Biomater Sci 2020;8:758-62. [DOI: 10.1039/c9bm01738k] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
8 Lokras A, Thakur A, Wadhwa A, Thanki K, Franzyk H, Foged C. Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Front Bioeng Biotechnol 2020;8:601155. [PMID: 33520957 DOI: 10.3389/fbioe.2020.601155] [Reference Citation Analysis]
9 Younis MA, Khalil IA, Elewa YHA, Kon Y, Harashima H. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. J Control Release 2021;331:335-49. [PMID: 33484779 DOI: 10.1016/j.jconrel.2021.01.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Carvalho BG, Vit FF, Carvalho HF, Han SW, de la Torre LG. Recent advances in co-delivery nanosystems for synergistic action in cancer treatment. J Mater Chem B 2021;9:1208-37. [PMID: 33393582 DOI: 10.1039/d0tb02168g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rahman M, Alharbi KS, Alruwaili NK, Anfinan N, Almalki WH, Padhy I, Sambamoorthy U, Swain S, Beg S. Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy. Expert Opinion on Drug Delivery 2020;17:805-16. [DOI: 10.1080/17425247.2020.1757645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
12 Bidram E, Esmaeili Y, Amini A, Sartorius R, Tay FR, Shariati L, Makvandi P. Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside. ACS Biomater Sci Eng 2021;7:2150-76. [PMID: 33979143 DOI: 10.1021/acsbiomaterials.1c00318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Xu Y, Harinck L, Lokras AG, Gerde P, Selg E, Sjöberg CO, Franzyk H, Thakur A, Foged C. Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. Int J Pharm 2022;:121758. [PMID: 35483619 DOI: 10.1016/j.ijpharm.2022.121758] [Reference Citation Analysis]
14 Huang Z, Huang Y, Wang W, Fu F, Wang W, Dang S, Li C, Ma C, Zhang X, Zhao Z, Pan X, Wu C. Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery. J Control Release 2020;325:206-22. [PMID: 32619747 DOI: 10.1016/j.jconrel.2020.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wu L, Wu LP, Wu J, Sun J, He Z, Rodríguez-Rodríguez C, Saatchi K, Dailey LA, Häfeli UO, Cun D, Yang M. Poly(lactide-co-glycolide) Nanoparticles Mediate Sustained Gene Silencing and Improved Biocompatibility of siRNA Delivery Systems in Mouse Lungs after Pulmonary Administration. ACS Appl Mater Interfaces 2021;13:3722-37. [PMID: 33439616 DOI: 10.1021/acsami.0c21259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kadekar S, Nawale GN, Rangasami VK, Le Joncour V, Laakkonen P, Hilborn J, Varghese OP, Oommen OP. Redox responsive Pluronic micelle mediated delivery of functional siRNA: a modular nano-assembly for targeted delivery. Biomater Sci 2021;9:3939-44. [PMID: 34002185 DOI: 10.1039/d1bm00428j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Taschauer A, Polzer W, Pöschl S, Metz S, Tepe N, Decker S, Cyran N, Scholda J, Maier J, Bloß H, Anton M, Hofmann T, Ogris M, Sami H. Combined Chemisorption and Complexation Generate siRNA Nanocarriers with Biophysics Optimized for Efficient Gene Knockdown and Air-Blood Barrier Crossing. ACS Appl Mater Interfaces 2020;12:30095-111. [PMID: 32515194 DOI: 10.1021/acsami.0c06608] [Reference Citation Analysis]
18 Kubczak M, Michlewska S, Bryszewska M, Aigner A, Ionov M. Nanoparticles for local delivery of siRNA in lung therapy. Adv Drug Deliv Rev 2021;179:114038. [PMID: 34742826 DOI: 10.1016/j.addr.2021.114038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ullah A, Qazi J, Rahman L, Kanaras AG, Khan WS, Hussain I, Rehman A. Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS-COV-2. Nano Sel 2020. [PMID: 34485978 DOI: 10.1002/nano.202000125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]